Peptide dossiers

One page per peptide. Each pulls together the regulatory actions, registered trials, published studies, patents and company filings, and links every claim to the document it came from. Where we could not check something, the page says so.

Available

• BPC-157

  FDA safety-risk listing and five warning letters, the July advisory committee vote, WADA status, four registered trials, a 2025 systematic review and a 1997 patent family.

  Not approvedEnforcement paused, conditions applyWADA prohibited

  Updated Oct 31, 2026

Not yet written

The other peptides on our status tracker. They get a link here once a dossier is done.

• TB-500
• KPV
• MOTS-c
• Semax
• Epitalon
• Emideltide (DSIP)
• LL-37
• GHK-Cu
• Dihexa
• Melanotan II
• PEG-MGF

How we build them

• Primary documents only: agency pages and letters, journal abstracts, the trial registry, company filings, patent records.
• We never link to sellers. Seller names appear only where a government document names them.
• Advocacy and company statements are labeled as such.
• No dosing or medical advice.